Showing results (1221-1230 of 1,244) with videos related to

Sort By:
Pageof 125
Stroke|April 14, 2020
Clinical and Imaging Determinants of Collateral Status in Patients With Acute Ischemic Stroke in MR CLEAN Trial and RegistryEveline J A Wiegers, Maxim J H L Mulder, Ivo G H Jansen, et al.
Clinical Epigenetics|November 6, 2019
A genome-wide DNA methylation signature for SETD1B-related syndromeI M Krzyzewska, S M Maas, P Henneman, et al.
JAMA Network Open|March 15, 2022
Risk Factors Associated With Mortality and Neurologic Disability After Intracerebral Hemorrhage in a Racially and Ethnically Diverse CohortDaniel Woo, Mary E Comeau, Simone Uniken Venema, et al.
BMJ Oncology|January 31, 2025
Regional disparities in the use of intensive chemotherapy for AML in the Netherlands: does it influence survival?Z L Rana Kaplan, Nikki van Leeuwen, David van Klaveren, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 6, 2021
Clinical epigenomics: genome-wide DNA methylation analysis for the diagnosis of Mendelian disordersBekim Sadikovic, Michael A Levy, Jennifer Kerkhof, et al.
JAMA Neurology|July 31, 2023
Development and Validation of a Postprocedural Model to Predict Outcome After Endovascular Treatment for Ischemic StrokeVicky Chalos, Esmee Venema, Maxim J H L Mulder, et al.
Blood|January 5, 2017
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AMLBob Löwenberg, Thomas Pabst, Johan Maertens, et al.
Stroke and Vascular Neurology|April 8, 2021
Endovascular treatment in anterior circulation stroke beyond 6.5 hours after onset or time last seen well: results from the MR CLEAN RegistryLuuk Dekker, Esmee Venema, F Anne V Pirson, et al.
Molecular Genetics and Metabolism|October 15, 2011
The 48-hour tetrahydrobiopterin loading test in patients with phenylketonuria: evaluation of protocol and influence of baseline phenylalanine concentrationK Anjema, G Venema, F C Hofstede, et al.
Blood Advances|September 11, 2020
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDSGerwin Huls, Dana A Chitu, Thomas Pabst, et al.
Pageof 125